IDEAS home Printed from https://ideas.repec.org/a/ibn/gjhsjl/v10y2018i10p152.html
   My bibliography  Save this article

A Comparative Study on Medicine Pricing in Brazil, Russia, India, China and South Africa (BRICS)

Author

Listed:
  • Varsha Bangalee
  • Fatima Suleman

Abstract

BACKGROUND- It is well documented that high prices hinder access to medicines to a large percentage of the population in low- and middle-income countries. It is with this in mind that governments have made attempts to control medicine pricing with the intent to protect and promote a country’s overall health. BRICS as Brazil, Russia, India, China and South Africa have collectively become to be known, represent five newly emerging global economies, each one attempting to control medicine pricing and improve accessibility. OBJECTIVE- To compare the medicine pricing regulatory efforts made by each of the BRICS countries. METHOD- This was achieved through the dissemination of an online survey posed to members of the BRICS Medicines Alliance. Questions in the survey looked at the presence of an essential’s medicines list; pricing regulations and control measures employed at the manufacturer, wholesaler and retail level. RESULTS- The findings reveal that each country has adopted different paths and time frames toward policy and regulatory development. CONCLUSION- Despite the variations in policy adoption, shared lessons can still be learnt from each country to improve the outcomes for each individual country and create an opportunity for pharmaceutical growth and transparency in medicine pricing.

Suggested Citation

  • Varsha Bangalee & Fatima Suleman, 2018. "A Comparative Study on Medicine Pricing in Brazil, Russia, India, China and South Africa (BRICS)," Global Journal of Health Science, Canadian Center of Science and Education, vol. 10(10), pages 152-152, October.
    • Handle: RePEc:ibn:gjhsjl:v:10:y:2018:i:10:p:152
    as

    Download full text from publisher

    File URL: http://www.ccsenet.org/journal/index.php/gjhs/article/download/0/0/36973/37069
    Download Restriction: no
    File URL: http://www.ccsenet.org/journal/index.php/gjhs/article/view/0/36973
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Samira Guennif & Shyama V. Ramani, 2010. "Catching up in pharmaceuticals: a comparative study of India and Brazil," Working Papers hal-00632439, HAL.
    2. Guennif, Samir & Ramani, Shyama, 2010. "Catching up in pharmaceuticals: a comparative study of India and Brazil," MERIT Working Papers 2010-019, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
    3. Shanlian Hu & Yabing Zhang & Jiangjiang He & Lixia Du & Mingfei Xu & Chunyan Xie & Ying Peng & Linan Wang, 2015. "A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 13-20, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Varma, Sumati & Nayyar, Rishika, 2014. "OFDI between India and the LAC Region : A firm level motive analysis," MPRA Paper 56219, University Library of Munich, Germany.
    2. Daems, Rutger & Maes, Edith & Ramani, Shyama V., 2011. "Global Framework for Differential Pricing of Pharmaceuticals," MERIT Working Papers 2011-054, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
    3. Livio Garattini & Katelijne Vooren, 2015. "Safety and Quality of Generic Drugs: A Never Ending Debate Fostered by Economic Interests?," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 3-4, August.
    4. Toon van der Gronde & Carin A Uyl-de Groot & Toine Pieters, 2017. "Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-34, August.

    More about this item

    JEL classification:

    • R00 - Urban, Rural, Regional, Real Estate, and Transportation Economics - - General - - - General
    • Z0 - Other Special Topics - - General

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ibn:gjhsjl:v:10:y:2018:i:10:p:152. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Canadian Center of Science and Education (email available below). General contact details of provider: https://edirc.repec.org/data/cepflch.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.